<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - Impel NeuroPharma Presents Data From Phase III Registration Study For The Treatment Of Acute Migraine
Image Overlay - Impel NeuroPharma Presents Data From Phase III Registration Study For The Treatment Of Acute Migraine

Impel NeuroPharma Presents Data From Phase III Registration Study For The Treatment Of Acute Migraine

October 12, 2020

Impel NeuroPharma Presents Data From Phase III Registration Study For The Treatment Of Acute Migraine

Impel NeuroPharma presented patient-reported outcomes data from the company's pivotal phase III, open-label study "STOP 301" of INP104 (dihydroergotamine mesylate) using the company's proprietary POD technology, for the treatment of acute migraine. Yourway is committed to supporting clinical trials for unmet medical needs.

 Back to Index
Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Precision in Pharma Supply Chain & Logistics Summit

November 17-18, 2025
Revere Hotel Boston Common

SCOPE Supply Chain & Logistics Leadership Summit

February 2-5, 2026
Orlando, Florida

Media

Articles

Mitigating Risk in Drug Development: The Strategic Role of Phase I Research Units

Open chat
Come chat with us!
Hello! How can I help you?